Addex Therapeutics Ltd ADRADXN
Price$2.76

Financial Snapshot

Revenue, profitability, returns, debt, and capital allocation

Revenue $445.6K-76.8% YoYTTM through 30 Jun 2025
Net Income $7.8MTTM through 30 Jun 2025
Free Cash Flow -$6.8MTTM through 30 Jun 2025

Margins

Current
EBITDA Margin-575.0%
Operating Margin-681.8%
Net Margin1,746.0%

Returns

-140.6%ROE
-105.3%ROA

Balance Sheet Health

Debt / Equity0.00x
Current Ratio0.97x
Net Debt-$1.6Mnet cash position
Cash & Equivalents$2.3M

Quality Metrics

Piotroski F-Score3 / 9
FCF Margin-1,521.5%

Multi-Year Trend

Diluted EPS
'18'19'20'21'22'23'24
FY2024: $0.07

Dividend

No dividend

Capital Allocation

Capex Intensity0.3%
Financials converted at 0.7927 from CHF.
All values are periodic snapshots, not live quotes. Source dates are shown for reference.

Filing Detail Members

This section is available to registered members. Create a free account or sign in to unlock the full breakdown.

Sign in / Sign up
AI-assisted, source-linked narrative; figures from company filings (SEC EDGAR) and market data. Dates shown per section. Not investment advice. Terms of Use.